Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1109
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 349–360 of 1,109 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

NCT07328581
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
Biological
Lead sponsor
iCell Gene Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Hawthorne, New York • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

NCT06566079
Status at this site: Recruiting
View directory record Official record
Conditions
Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Interventions
ISM6331
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemias
Interventions
Revumenib, Chemotherapy Regimen, HiDAC
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Goodyear, Arizona • Burbank, California • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

VIBRANT: VIB4920 for Active Lupus Nephritis

NCT05201469
Status at this site: Recruiting
View directory record Official record
Conditions
Lupus Nephritis
Interventions
VIB4920, Placebo for VIB4920
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232
Site status not listed — check the official record
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions
Divarasib, Sotorasib, Adagrasib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410
Status at this site: Recruiting
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Cemiplimab, Standard of care
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Valemetostat tosylate, T-DXd, Dato-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Irvine, California • San Diego, California • Plantation, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
Status at this site: Recruiting
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Tocilizumab for Acute Chest Syndrome

NCT05640271
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663
Site status not listed — check the official record
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Gemcitabine, Docetaxel, Bacillus Calmette Guerin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
229
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:36 AM EDT

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.